The debate: The trials have told us very little

References

• Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101–111
   PubMed Web of Science ®Google Scholar
• EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86: 668–672
   PubMed Web of Science ®Google Scholar
• Burch PA, Karp JE, Merz WG, Kuhlman JE, Fishman EK. Favourable outcome of invasive aspergillosis in patients with acute leukaemia. J Clin Oncol 1987; 5: 1985–1993
   PubMed Web of Science ®Google Scholar
• Kaiser L, Huguenin T, Lew PD, Chapuis B, Pitter D. Invasive aspergillosis. Clinical features of 35 proven cases at a single institution. Medicine (Baltimore) 1987; 77: 188–194
   Google Scholar
• Verweij PE, Donnelly JP, Kullberg BJ, Meis JFGM, de Pauw BE. Amphotericin B versus Amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection 1994; 22: 81–85
   PubMed Web of Science ®Google Scholar
• Bodey GP, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: An international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11: 99–109
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Rubin M, Hathorn J, et al. Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study. Arch Int Med 1991; 151: 765–770
   PubMed Web of Science ®Google Scholar
• Marie JP, Lapierre V, Pico J, et al. tude multicentrique randomisee fluconazole IV versus amphotéricine B IV chez le patient neutropénique et fébrile. Cahiers Oncol 1993; 2: 171–173
   Google Scholar
• Viscoli C, Castagnola E, Van Lint MT, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 1996; 32: 814–820
   Google Scholar
• Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000; 108: 282–289
   PubMed Web of Science ®Google Scholar
• Ellis ME, Halim MA, Spence D, et al. Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever – preliminary observations from a pilot, exploratory study. J Infect 1995; 30: 141–146
   PubMed Web of Science ®Google Scholar
• Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998; 105: 478–483
   PubMed Web of Science ®Google Scholar
• Silling G, Fegeler W, Roos N, Essink M, Buchner T. Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine. Mycoses 1999; 42(Suppl. 2)101–104
   Google Scholar
• Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Int Med 2001; 135: 412–422
   PubMed Web of Science ®Google Scholar
• Ehninger G, Schuler U, Bammer S, , et al. Intravenous itraconazole followed by oral itraconazole versus intravenous amphotericin B as empirical antifungal therapy for febrile neutropenic haematological cancer patients. Blood 2002; 100((Suppl.)): 42b [abstract].
   Google Scholar
• Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711–718
   PubMed Web of Science ®Google Scholar
• White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of Amphotericin B colloidal dispersion vs. Amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27: 296–302
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764–771
   PubMed Web of Science ®Google Scholar
• Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31: 1155–1163
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225–234
   PubMed Web of Science ®Google Scholar
• Walsh T, Sable C, de Pauw B, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391–1402
   PubMed Web of Science ®Google Scholar
• Hebart H, Klingspor L, , et al. PCR-based liposomal amphotericin B treatment following allogeneic stem cell transplantation is a safe treatment strategy: preliminary results of a prospective study. Blood 2004; 104((Suppl.)), 59a [abstract].
   Google Scholar
• Maertens J, Theinissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prosepective feasibility study. Clin Infect Dis 2005; 41: 1242–1250
   PubMed Web of Science ®Google Scholar
• Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359–366
   PubMed Web of Science ®Google Scholar
• Ellis M, Spence D, de Pauw B, et al. An EORTC international randomised trial comparing two doses of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27: 1406–1412
   PubMed Web of Science ®Google Scholar
• Leenders AC, Daenen S, Jansen RLH, et al. Liposomal Amphotericin B compared with Amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998; 103: 205–212
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, De Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14
   PubMed Web of Science ®Google Scholar
• Slavin MA, Osborne B, Adams R , et al Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomised, double-blind study. J Infect Dis 171: 1545–1552.
   PubMed Web of Science ®Google Scholar
• Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89: 1611–1625
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055–2061
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358–4366
   PubMed Web of Science ®Google Scholar
• Bow EJ, Laverdiere M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94: 3230–3246
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Prentice AG, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for haematological malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21: 4616–4626
   Web of Science ®Google Scholar
• Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19: 801–808
   PubMed Web of Science ®Google Scholar
• Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116: 475–482
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, , et al. Posaconazole versus fluconazole for prophylaxis of invasive fungal infection allogeneic stem cell transplant recipients with graft-versus-host-disease: results of a multicentre trial. 45th ICAACWashington, 2005.
   Google Scholar
• Cornely O, Maertens J, Winston D, , et al. Posaconazole versus standard azole (flu/itra) therapy for prophylaxis of invasive fungal infections among high risk neutropenic patients: results of a randomised multicentre trial. Blood 2005; 106((Suppl.)): 524a [abstract].
   Google Scholar
• van Burik JAH, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407–1416
   PubMed Web of Science ®Google Scholar